CN110669054B - 胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途 - Google Patents
胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途 Download PDFInfo
- Publication number
- CN110669054B CN110669054B CN201810711045.8A CN201810711045A CN110669054B CN 110669054 B CN110669054 B CN 110669054B CN 201810711045 A CN201810711045 A CN 201810711045A CN 110669054 B CN110669054 B CN 110669054B
- Authority
- CN
- China
- Prior art keywords
- compound
- trimethoxyphenyl
- dioxol
- naphtho
- difluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 title claims abstract description 14
- 101710184277 Insulin-like growth factor 1 receptor Proteins 0.000 title claims abstract description 11
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 58
- 201000007983 brain glioma Diseases 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 125000005809 3,4,5-trimethoxyphenyl group Chemical group [H]C1=C(OC([H])([H])[H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 claims description 19
- 229910052805 deuterium Inorganic materials 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 9
- 239000001257 hydrogen Substances 0.000 claims description 9
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 206010003571 Astrocytoma Diseases 0.000 claims description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims description 3
- AEWCVNHOFJWFTF-FTNBBQJZSA-N (5R,5aR,8aS,9R)-2,2-difluoro-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound FC1(OC2=C(O1)C=C1[C@@H]([C@@H]3[C@H]([C@@H](C1=C2)C2=CC(=C(C(=C2)OC)OC)OC)C(OC3)=O)O)F AEWCVNHOFJWFTF-FTNBBQJZSA-N 0.000 claims description 2
- MPKOVGUTMGCUQP-VEFTVXKRSA-N (5S,5aR,8aS,9R)-2,2,5-trifluoro-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound FC1(OC2=C(O1)C=C1[C@H]([C@@H]3[C@H]([C@@H](C1=C2)C2=CC(=C(C(=C2)OC)OC)OC)C(OC3)=O)F)F MPKOVGUTMGCUQP-VEFTVXKRSA-N 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
- LPPZLIUZKZXITJ-DJJZHVJBSA-N [(5R,5aR,8aS,9R)-2,2-difluoro-8-oxo-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-5-yl] acetate Chemical compound C(C)(=O)O[C@H]1C2=CC3=C(OC(O3)(F)F)C=C2[C@H]([C@H]2[C@@H]1COC2=O)C2=CC(=C(C(=C2)OC)OC)OC LPPZLIUZKZXITJ-DJJZHVJBSA-N 0.000 claims description 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 37
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 25
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 22
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
- 238000005160 1H NMR spectroscopy Methods 0.000 description 16
- 239000012074 organic phase Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- 235000019439 ethyl acetate Nutrition 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 239000007787 solid Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 210000005013 brain tissue Anatomy 0.000 description 10
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 10
- 239000011541 reaction mixture Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 9
- 235000019341 magnesium sulphate Nutrition 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 229940125904 compound 1 Drugs 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 229960001237 podophyllotoxin Drugs 0.000 description 7
- YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 6
- 210000001218 blood-brain barrier Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000010568 chiral column chromatography Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 230000019491 signal transduction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- -1 (3,4, 5-trimethoxyphenyl) methyl Chemical group 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 229940125782 compound 2 Drugs 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- YJGVMLPVUAXIQN-HAEOHBJNSA-N picropodophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-HAEOHBJNSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229940126214 compound 3 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OPHQOIGEOHXOGX-UHFFFAOYSA-N 3,4,5-trimethoxybenzaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1OC OPHQOIGEOHXOGX-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- 102000029749 Microtubule Human genes 0.000 description 2
- 108091022875 Microtubule Proteins 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000003576 central nervous system agent Substances 0.000 description 2
- 229940125773 compound 10 Drugs 0.000 description 2
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000004688 microtubule Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000002733 pharmacodynamic assay Methods 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 1
- CRUILBNAQILVHZ-UHFFFAOYSA-N 1,2,3-trimethoxybenzene Chemical compound COC1=CC=CC(OC)=C1OC CRUILBNAQILVHZ-UHFFFAOYSA-N 0.000 description 1
- VNSQXWISTNFYFV-UHFFFAOYSA-N 1,3-dioxol-4-ol Chemical compound OC1=COCO1 VNSQXWISTNFYFV-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- AUJAAMXYEHZSLP-UHFFFAOYSA-N 4-ethenyloxolan-2-one Chemical class C=CC1COC(=O)C1 AUJAAMXYEHZSLP-UHFFFAOYSA-N 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910003827 NRaRb Inorganic materials 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 241001495452 Podophyllum Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- VORIUEAZEKLUSJ-UHFFFAOYSA-M [(6-chlorobenzotriazol-1-yl)oxy-(dimethylamino)methylidene]-dimethylazanium;trifluoroborane;fluoride Chemical compound [F-].FB(F)F.C1=C(Cl)C=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 VORIUEAZEKLUSJ-UHFFFAOYSA-M 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 208000030224 brain astrocytoma Diseases 0.000 description 1
- 210000004781 brain capillary Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000036456 mitotic arrest Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Chemical group 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 235000021178 picnic Nutrition 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000012354 sodium borodeuteride Substances 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一类可作为胰岛素样生长因子‑1受体酪氨酸激酶抑制剂的化合物,制备它们的方法,包含所述化合物的药物组合物及其药物组合物在预防或治疗肿瘤,尤其脑部胶质瘤的应用。
Description
技术领域
本发明涉及药物化学领域,具体涉及胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途。
背景技术
胰岛素样生长因子-1受体(IGF-1R)是酪氨酸蛋白激酶家族的成员,其信号传导途径与肿瘤发生密切相关,在恶性细胞的增生、对抗细胞凋亡及转变中起着重要作用。
环木脂体鬼臼毒素(Podophyllotoxin)是从小蘖科鬼臼属植物中提取的天然产物,其可以与β-微管蛋白结合以引起微管聚集抑制和有丝分裂的停顿,但其毒副作用阻碍了其在抗癌药物领域的发展。
专利文献WO2002102804A显示,鬼臼毒素在内酯环上具有顺式结构的立体异构体鬼臼苦素(Picropodophyllin,PPP)具有良好的IGF-1R抑制的活性,并且由于其空间构型与微管结合的低亲和性,其毒性与鬼臼毒素相比大大降低。
血脑屏障(blood brain barrier,BBB)是指脑毛细血管壁与神经胶质细胞形成的血浆与脑细胞之间的屏障和由脉络丛形成的血浆和脑脊液之间的屏障,这些屏障能够阻止某些物质由血液进入脑组织,它在保护中枢神经系统免受外来物质干扰和伤害的同时,也阻碍了许多潜在的中枢神经系统药物进入中枢,增加了中枢神经系统药物研发的难度。
PPP虽然具有良好的IGF-1R抑制的活性和较低的毒性,但在研究中发现,其BBB通透性不佳,难以在脑部胶质瘤中发挥作用,如星形细胞瘤。
发明内容
本发明公开了一类可作为胰岛素样生长因子-1受体酪氨酸激酶抑制剂的化合物,具有如预防或治疗肿瘤,尤其脑部胶质瘤的用途。
一方面,本发明提供式(I)化合物、其立体异构体或其药学上可接受的盐:
在一些实施例中,两个R1分别独立的选自氢、卤素、取代或非取代的C1-8烷基;或者两个R1与连接它们的碳原子一起形成非取代或取代的具有0-4个独立选自氮、氧或硫杂原子的单环或二环;且两个R1不同时为氢;
R2和R3分别独立的选自氢、氘、卤素、羟基、取代或非取代的C1-8烷基、-ORa、-O(C=O)Ra、-O(C=O)NRaRb;
Ra和Rb分别独立的选自取代或非取代的C1-8烷基,取代基选自氘或卤素;
R4和R5分别独立的选自氢、氘、C1-8烷基、
在另一些实施例中,两个R1分别独立的选自氟或甲基;
R2和R3分别独立的选自氢、氘、卤素、羟基、甲氧基或乙酰氧基;
R4和R5分别独立的选自氢、氘、C1-8烷基、
在另一些实施例中,两个R1都为氟。
在另一些实施例中,所述化合物选自:
Rel-(5R,5aS,8aR,9R)-2,2-二氟-9-羟基-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6(5aH)-酮;
Rel-(5R,5aR,8aS,9R)-2,2-二氟-8-氧代-9-(3,4,5-三甲氧基苯基)-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-5-基乙酸酯;
Rel-(5R,5aS,8aR,9S)-2,2,9-三氟-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6(5aH)-酮;
Rel-(5R,5aS,8aR,9R)-2,2-二氟-9-甲氧基-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4'6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6-(5aH)-酮;
Rel-(5R,5aS,8aR,9R)-2,2-二氟-9-羟基-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6-(5aH)-酮-9-氘;
(5R,5aS,8aR,9R)-2,2-二氟-9-羟基-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6(5aH)-酮;
(5R,5aS,8aR,9R)-2,2-二氟-9-羟基-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6-(5aH)-酮-9-氘;
(5R,5aR,8aS,9R)-2,2-二氟-8-氧代-9-(3,4,5-三甲氧基苯基)-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-5-基乙酸酯;
(5R,5aS,8aR,9S)-2,2,9-三氟-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6(5aH)-酮;
(5R,5aS,8aR,9R)-2,2-二氟-9-甲氧基-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4'6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6-(5aH)-酮。
在另一些实施例中,所述化合物具有如下相对构型的结构:
在另一些实施例中,所述化合物具有如下绝对构型的结构:
另一方面,本发明提供一种药物组合物,所述药物组合物包括本发明化合物、其立体异构体或其药学上可接受的盐,和药学上可用的载体。
另一方面,本发明提供前述化合物、其立体异构体或其药学上可接受的盐在制备胰岛素样生长因子-1受体酪氨酸激酶抑制剂类药物中的用途。
另一方面,本发明提供前述化合物、其立体异构体或其药学上可接受的盐在制备预防或治疗抗肿瘤药物中的用途。
在一些实施例中,所述肿瘤为脑部胶质瘤。
在另一些实施例中,所述脑部胶质瘤为星形细胞瘤。
下面简写词的使用贯穿本发明:
THF:四氢呋喃;
LDA:二异丙基氨基锂;
EtOAc:乙酸乙酯;
PE:石油醚;
DCM:二氯甲烷;
CDCl3:氘代氯仿;
Et3N:三乙胺;
Tf2O:三氟甲磺酸酐;
PPh3:三苯基膦;
MeOH:甲醇;
FBS:染色缓冲液;
EDTA:乙二胺四乙酸;
DMSO:二甲亚砜;
SDS-PAGE:十二烷基硫酸钠聚丙烯酰胺凝胶电泳;
PVDF:聚偏二氟乙烯。
附图说明
图1为实验例2化合物透过血脑屏障实验-IGF1R信号通路生物标志物检测的全自动化学发光/荧光图像分析系统成像图;
图2为本发明化合物2与PPP(苦鬼臼毒素)以50mg/kg灌胃给药1-3小时后在小鼠脑组织和血浆中的含量图;
图3为本发明化合物5与化合物6以50mg/kg灌胃给药1-3小时后在小鼠脑组织和血浆中的含量图;
图4为本发明化合物6以50mg/kg灌胃给药1-24小时在小鼠脑组织和血浆中的含量图;
图5为本发明化合物7以25mg/kg灌胃给药1-24小时在小鼠脑组织和血浆中的含量图。
具体实施方式
实施例1
化合物1:Rel-(5R,5aS,8aR,9R)-2,2-二氟-9-羟基-5-(3,4,5-三甲氧基苯基)-5,
8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6(5aH)-酮
中间体1.1的合成:4-乙烯基二氢呋喃-2(3H)-酮
搅拌下将2-丁烯-1,4-二醇(206.4g,2.34mol,1.0e.q.)溶于原乙酸三乙酯(546.7g,3.4mol,1.4e.q.)中,加入催化氢醌(54.00g,0.49mol,0.2e.q.),并将所得混合物加热至120℃。原位形成的乙醇连续馏出直至不再有乙醇产生。将温度升至150℃,并将反应混合物再搅拌48小时。通过真空蒸馏(70~75℃,2~3mmHg)收集中间体1.1,为无色油状物(170.0g,收率65%)。1HNMR(400MHz,CDCl3)δ(ppm)2.36(dd,J=17.4Hz,8.7Hz,1H),2.69(dd,J=17.7Hz,8.4Hz,1H),3.19-3.29(m,1H),4.01-4.14(m,1H),4.43-4.47(m,1H),5.17-5.23(m,2H),5.75-5.84(m,1H)。
中间体1.2的合成:Rel-(3S,4R)-3-(羟基(3,4,5-三甲氧基苯基)甲基)-4-乙烯基
二氢呋喃-2(3H)-酮
在-78℃和氮气条件下,搅拌下将中间体1.1(170.0g,1.52mol,1.0e.q.)溶于THF中(1500mL),搅拌滴加LDA(2.0M,834mL,1.67mol,1.1e.q.)将反应混合物再搅拌30分钟。在相同条件下滴加3,4,5-三甲氧基苯甲醛(327.6g,1.67mol,1.1e.q.)的THF(1500mL)溶液,并将所得混合物再搅拌3小时,然后逐渐升温至环境温度过夜。将反应混合物冷却至-78℃,并用饱和氯化铵水溶液淬灭。所得混合物用EtOAc萃取,用盐水洗涤有机相,用硫酸镁干燥,过滤并浓缩。通过柱色谱法(200~300目硅胶,PE/EtOAc=5/1~1/1)纯化,得到中间体1.2,为浅黄色固体(190.1g,收率41%)。1HNMR(400MHz,CDCl3)δ(ppm)2.75-2.80(m,1H),2.91-2.96(m,0.5H),3.26-3.31(m,0.5H),3.84(s,3H),3.89(s,6H),3.92(t,1H),4.30-4.40(m,1H),4.86-4.93(m,2H),6.59(s,1H),6.61(s,1H)。
中间体1.3的合成:Rel-(3R,4R)-3–((R)-(2,2-二氟-6-羟基苯并[d][1,3]间二氧
杂环戊烯-5-基)(3,4,5-三甲氧基苯基)甲基)-4-乙烯基二氢-2(3H)-呋喃酮
搅拌下将中间体1.2(106.7g,0.41mol,1.0e.q.)和2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-醇(107.6g,0.61mol,1.5e.q.)溶于DCM(2000mL)中,加入FeCl3(34.06g,0.20mol,0.5e.q.),并将混合物加热至40℃反应2~3小时。将反应混合物用饱和碳酸氢钠水溶液淬灭,并将水相用另外的DCM萃取。用盐水洗涤有机相,用硫酸镁干燥,过滤并浓缩。通过柱色谱法(200~300目硅胶,PE/EtOAc=5/1~1/1)纯化,得到中间体1.3(153.4g,收率45%),为灰白色固体。1HNMR(400MHz,CDCl3)δ(ppm)3.02-3.06(m,1H),3.19-3.21(m,1H),3.83(s,6H),3.88(s,3H),4.04-4.07(m,1H),4.25-4.29(m,1H),4.73-4.75(d,J=4.8Hz,1H),5.14-5.22(m,2H),5.55(brs,1H),5.80-5.84(m,1H),6.51-6.59(m,2H),6.82-6.96(m,1H),7.29(s,1H)。
中间体1.4的合成:Rel-2,2-二氟-6-((R)-((3R,4R)-2-氧代-4-乙烯基四氢呋喃-
3-基)(3,4,5-三甲氧基苯基)甲基)苯并[d][1,3]间二氧杂环戊烯-5-基三氟甲磺酸酯
搅拌下将中间体1.3(120.0g,0.26mol,1.0e.q.)溶于DCM(1500mL)中,加入Et3N(52.62g,0.52mol,2.0e.q.),接着滴加Tf2O(110.0g,0.39mol,1.5e.q.),并在相同温度下将所得混合物再搅拌30分钟。将反应混合物用饱和碳酸氢钠溶液淬灭,并将水相用另外的DCM萃取。将合并的有机相用2M盐酸洗涤,用盐水洗涤有机相,用硫酸镁干燥,过滤并浓缩。通过柱色谱法(200~300目硅胶,PE/EtOAc=6/1~3/1)纯化,得到中间体1.4(120.0g,收率61%),为白色固体。1HNMR(400MHz,CDCl3)δ(ppm)2.97-3.06(m,1H),3.13-3.17(m,1H),3.84(s,6H),3.85(s,3H),4.03-4.08(m,1H),4.37-4.41(m,1H),4.64-4.66(d,J=8.3Hz,1H),5.08-5.20(dt,2H),5.71-5.80(m,1H),6.58(s,2H),7.04(s,1H),7.23(s,1H)。
中间体1.5的合成:Rel-(5R,5aR,8aS)-2,2-二氟-9-亚甲基-5-(3,4,5-三甲氧基
苯基)-5,8,8a,9-四氢呋喃并[3',4':6.7]萘并[2,3-d][1,3]间二氧杂环戊烯-6-(5aH)-酮
搅拌下将中间体1.4(120.0g,0.20mol,1.0e.q.)溶于乙腈(1500mL),加入PPh3(15.83g,60.0mmol,0.3e.q.),碳酸钾(82.93g,0.60mol,3.0e.q.)和醋酸钯(4.49g,20.0mmol,10mol%),并将所得混合物加热至80℃反应20小时。过滤反应混合物,滤饼用DCM洗涤。将合并的有机相浓缩,通过柱色谱法(200~300目硅胶,PE/EtOAc=5/1~1/1)纯化,得到中间体1.5(76.13g,收率61%),为白色固体。1HNMR(400MHz,CDCl3)δ(ppm)3.31-3.34(dd,1H),3.65-3.68(t,1H),3.76(s,6H),3.84(s,3H),4.21-4.24(dd,1H),4.57-4.59(m,2H),5.21-5.22(d,1),5.57(s,1H),6.31(s,2H),6.95(s,1H),7.27(s,1H)。
中间体1.6的合成:Rel-(5aR,8aR,9R)-2,2-二氟-9-(3,4,5-三甲氧基苯基)-5a,
6,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-5,8-二酮
搅拌下将中间体1.5(79.04g,0.18mol,1.0e.q.)和N-甲基吗啉-N-氧化物(168.7g,0.72mol,3.0e.q.)加入DCM(1200mL)中,加入四氧化锇(4.00g,15.7mmol,8mol%),并将反应混合物在室温下搅拌12小时。分批加入固体高碘酸钠(77.00g,0.36mol,2.0e.q.),并将得到的混合物再搅拌1小时。在冰水浴温度下,用饱和硫代硫酸钠水溶液(300mL)淬灭反应混合物,用DCM萃取水相。将合并的有机相用盐水洗涤,有机相用硫酸镁干燥,过滤并浓缩。通过柱色谱法(200~300目硅胶,PE/EtOAc=5/1~1/1)纯化,得到中间体1.6(48.80g,收率60%),为白色固体。1HNMR(400MHz,CDCl3)δ(ppm)3.37-3.42(m,2H),3.78(s,6H),3.82(s,3H),4.38-4.42(m,1H),4.79-4.80(d,J=2.8Hz,2H),6.22(s,2H),7.02(s,1H),7.80(s,1H)。
化合物1的合成:Rel-(5R,5aS,8aR,9R)-2,2-二氟-9-羟基-5-(3,4,5-三甲氧基苯
基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6(5aH)-酮
在-78℃和氮气条件下,搅拌下将中间体1.6(43.30g,98.9mmol,1.0e.q.)溶于乙醚(1500mL),滴加三叔丁氧基氢化铝锂(200mL,197mmol,2.0e.q.),并将所得混合物逐渐升温至室温过夜。在冰水浴温度下用2M盐酸淬灭反应,并用另外的DCM萃取水相。将合并的有机相用盐水洗涤,有机相用硫酸镁干燥,过滤并浓缩。将获得的粗品从EtOAc中重结晶,得到呈白色固体的化合物1(33.10g,收率74%)。1HNMR(400MHz,CDCl3)δ(ppm)7.38(s,1H),6.53(s,1H),6.47(s,2H),4.67(d,J=0.9Hz,1H),4.55-4.43(m,2H),4.03(d,J=6.4Hz,1H),3.89(s,3H),3.85(s,6H),3.26(q,1H),2.96(d,J=6.9Hz,1H),2.66(m,1H)。
实施例2
化合物2:Rel-(5R,5aR,8aS,9R)-2,2-二氟-8-氧代-9-(3,4,5-三甲氧基苯基)-5,
5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-5-基乙酸酯
搅拌下将化合物1(1.15g,2.55mmol,1.0e.q.)溶于DCM(30mL),加入Et3N(770mg,7.6mmol,3.0e.q.),4-二甲氨基吡啶(310mg,2.55mmol,1.0e.q.),在冰水浴温度下加入乙酰氯(400mg,5.1mmol,2.0e.q.),并将所得混合物在环境温度下搅拌12小时。将反应混合物用饱和氯化铵水溶液淬灭,并将水相用另外的DCM萃取。将合并的有机相用盐水洗涤,有机相用硫酸镁干燥,过滤并浓缩。将获得的粗品从PE/EtOAc重结晶,得到呈白色固体的化合物2(810mg,65%收率)。1HNMR(400MHz,CDCl3)δ(ppm)7.02(s,1H),6.76(s,1H),6.41(s,2H),5.81(d,J=6.3Hz,1H),4.48-4.34(m,3H),3.87(s,3H),3.84(s,6H),3.32(d,1H),3.01(m,1H),2.12(s,3H)。
实施例3
化合物3:Rel-(5R,5aS,8aR,9S)-2,2,9-三氟-5-(3,4,5-三甲氧基苯基)-5,8,8a, 9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6(5aH)-酮
搅拌下将化合物1(700mg,1.60mmol,1.0e.q.)溶于DCM(20mL)中,滴加二乙胺基三氟化硫(520mg,3.20mmol,2.0e.q.),并将所得混合物在室温下搅拌12小时。将反应混合物用饱和碳酸氢钠水溶液淬灭,再搅拌30分钟。分离有机相,并用另外的DCM萃取水相。将合并的有机相用盐水洗涤,有机相用硫酸镁干燥,过滤并浓缩。通过柱色谱法(200~300目硅胶,DCM/MeOH=100/1~50/1)纯化,得到呈白色固体的化合物3(130mg,18%收率)。1HNMR(400MHz,CDCl3)δ(ppm)7.27(s,1H),6.66(s,1H),6.44(s,2H),5.49-5.34(m,1H),4.60-4.47(m,2H),4.20(d,J=5.0Hz,1H),3.88(s,3H),3.84(s,6H),3.28(m,1H),3.01(m,1H)。
实施例4
化合物4:Rel-(5R,5aS,8aR,9R)-2,2-二氟-9-甲氧基-5-(3,4,5-三甲氧基苯基)- 5,8,8a,9-四氢呋喃并[3',4'6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6-(5aH)-酮
搅拌下将化合物1(600mg,1.33mmol,1.0e.q.)溶于DCM(15mL)中,加入三甲基氧鎓四氟硼酸(246mg,1.66mmol,1.2e.q.),并将所得混合物在室温下搅拌20小时。反应用饱和碳酸氢钠水溶液淬灭,并再搅拌30分钟。分离有机相,并用另外的DCM萃取水相。将合并的有机相用盐水洗涤,有机相用硫酸镁干燥,过滤并浓缩。通过柱色谱(200~300目硅胶,DCM/MeOH=100/1~50/1)纯化,得到呈白色固体的化合物4(65mg,11%收率)。1HNMR(400MHz,CDCl3)δ(ppm)7.16(s,1H),6.74(s,1H),6.41(s,2H),4.45-4.36(m,3H),4.34(d,J=4.3Hz,1H),3.88(s,3H),3.83(s,6H),3.42(d,1H),3.31(s,3H),3.14(m,1H)。
实施例5
化合物5:Rel-(5R,5aS,8aR,9R)-2,2-二氟-9-羟基-5-(3,4,5-三甲氧基苯基)-5, 8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d]x[1,3]间二氧杂环戊烯-6-(5aH)-酮-9-氘
搅拌下将中间体1.6(400mg,0.89mmol,1.0e.q.)溶于甲醇(10mL),分批加入硼氘化钠(37.5mg,0.89mmol,1.0e.q.),并将所得混合物搅拌4小时。反应用水淬灭,并浓缩。将获得的残余物用水稀释,并用EtOAc萃取。将合并的有机相用盐水洗涤,有机相用硫酸镁干燥,过滤并浓缩。将获得的粗品从PE/EtOAc重结晶,得到呈白色固体的化合物5(140mg,35%收率)。1HNMR(400MHz,CDCl3)δ(ppm)7.38(s,1H),6.57(s,1H),6.47(s,2H),4.66(d,J=9.8Hz,1H),4.47(m,1H),4.06(d,J=6.2Hz,1H),3.89(s,3H),3.87(s,6H),3.27(d,1H),2.68(m,1H),2.44(s,1H)。
实施例6
化合物6:(5R,5aS,8aR,9R)-2,2-二氟-9-羟基-5-(3,4,5-三甲氧基苯基)-5,8, 8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6(5aH)-酮
通过在手性柱色谱上手性分离化合物1来制备化合物6,色谱条件如下:
仪器:Waters,SFC200
色谱柱:Daicel Chiralcel AD,250×50mm I.D.,10μm
流动相:A、CO2,B、异丙醇
梯度:B 20%
流速:150mL/min
背压:100bar
柱温:38℃
波长:220nm
循环时间:6.5分钟
样品制备:将化合物溶于约600mL MeOH中
注射:每次注射3mL
1HNMR(400MHz,CDCl3)δ(ppm)7.38(s,1H),6.53(s,1H),6.47(s,2H),4.67(d,J=0.9Hz,1H),4.55-4.43(m,2H),4.03(d,J=6.4Hz,1H),3.89(s,3H),3.85(s,6H),3.26(q,1H),2.96(d,J=6.9Hz,1H),2.66(m,1H);e.e.=98.56%;[α]=11.94°(MeOH,c=0.88g/100mL)。
实施例7
化合物7:(5R,5aS,8aR,9R)-2,2-二氟-9-羟基-5-(3,4,5-三甲氧基苯基)-5,8, 8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6-(5aH)-酮-9-氘
通过在手性柱色谱上手性分离化合物5来制备化合物7,色谱条件如下:
仪器:水SFC200
柱:Daicel Chiralcel AD,250×50mm I.D.,10μm
流动相:A、CO2,B、异丙醇
梯度:B 20%
流速:150mL/min
背压:100bar
柱温:38℃
波长:220nm
循环时间:6.5分钟
样品制备:将化合物溶于约600mL MeOH中
注射:每次注射3mL
1HNMR(400MHz,CDCl3)δ(ppm)7.38(s,1H),6.57(s,1H),6.47(s,2H),4.66(d,J=9.8Hz,1H),4.47(m,1H),4.06(d,J=6.2Hz,1H),3.89(s,3H),3.87(s,6H),3.27(d,1H),2.68(m,1H),2.44(s,1H)。
实施例8
化合物8:(5R,5aR,8aS,9R)-2,2-二氟-8-氧代-9-(3,4,5-三甲氧基苯基)-5,5a, 6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-5-基乙酸酯
通过在手性柱色谱上手性分离化合物2来制备化合物8,色谱条件参考实施例6。
1HNMR(400MHz,CDCl3)δ(ppm)7.02(s,1H),6.76(s,1H),6.41(s,2H),5.81(d,J=6.3Hz,1H),4.48-4.34(m,3H),3.87(s,3H),3.84(s,6H),3.32(d,1H),3.01(m,1H),2.12(s,3H)。
实施例9
化合物9:(5R,5aS,8aR,9S)-2,2,9-三氟-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四 氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6(5aH)-酮
通过在手性柱色谱上手性分离化合物3来制备化合物9,色谱条件参考实施例6。
1HNMR(400MHz,CDCl3)δ(ppm)7.27(s,1H),6.66(s,1H),6.44(s,2H),5.49-5.34(d,J=50.8Hz,1H),4.60-4.47(m,2H),4.20(d,J=5.0Hz,1H),3.88(s,3H),3.84(s,6H),3.28(m,1H),3.01(m,1H)。
实施例10
化合物10:(5R,5aS,8aR,9R)-2,2-二氟-9-甲氧基-5-(3,4,5-三甲氧基苯基)-5, 8,8a,9-四氢呋喃并[3',4'6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6-(5aH)-酮
通过在手性柱色谱上手性分离化合物4来制备化合物10,色谱条件参考实施例6。
1HNMR(400MHz,CDCl3)δ(ppm)7.16(s,1H),6.74(s,1H),6.41(s,2H),4.45-4.36(m,3H),4.34(d,J=4.3Hz,1H),3.88(s,3H),3.83(s,6H),3.42(d,1H),3.31(s,3H),3.14(m,1H)。
表1:本发明部分化合物的NMR、MS数据
实验例1:化合物体外药效学试验
试验方法与材料
细胞来源:人脑星形胶质母细胞瘤/胶质瘤细胞U-87MG(简称U87)购自中国科学院细胞库(上海),货号TCHu138;人胶质瘤细胞DBTRG-05MG(简称DBTRG)来自美国组织培养库ATCC,货号CRL-2020;人胶质瘤细胞KNS-81来自AcceGen Biotech,货号ABC-TC0535。
细胞培养和传代:上述细胞均贴壁培养于含完全培养基[含DMEM高糖基础培养液(#SH30243.01B,HyClone)加入终浓度为10%FBS(#1101-500,上海普飞)和Penicillin-Streptomycin双抗(#SV30010,HyClone)]的6cm培养皿(#430166,Corning)或T75培养瓶(#3276,Corning)中,培养皿(瓶)置于37℃,5%CO2,饱和湿度的细胞培养箱(#3111,ThermoFisher Scientific)中培养。传代时,先吸走培养基,用PBS磷酸缓冲盐溶液(#GNM-10944,杭州吉诺)洗涤2次,然后加入适量0.25%胰酶-0.02%EDTA(#25200-072,Gibco),摇晃培养皿(瓶)使之均匀覆盖细胞,置于相差显微镜下观察。待大多数细胞回缩变圆,轻摇即脱落时,迅速加入两倍胰酶体积的完全培养基终止,并轻轻将细胞吹打成单细胞。将细胞悬液移到合适大小的离心管内,800rpm离心5min。弃上清,用新鲜的完全培养重悬细胞团块,重新吹打成单细胞,以1:3-1:6的比率传代接种至新的培养皿(瓶)并补足完全培养基。置于37℃,5%CO2的细胞培养箱中培养。
细胞加药处理:将上述每种细胞消化、计数,均按5000细胞/200μL培养液的密度接种至96孔细胞培养板(#3988,Corning)的每个孔中,置于37℃,5%CO2的细胞培养箱中培养24h使细胞充分贴壁。然后分别将含梯度稀释后的各种待测化合物(每种化合物每个浓度设置3个重复孔)以及DMSO(#D5879,Sigma-Aldrich)溶剂对照的完全培养液替换掉原来的培养液,继续培养72h。
药效学测定和统计:先用倒置相差显微镜(X71,Olympus)对上述化合物处理后的细胞进行形态观察和拍照记录。然后分别将含CCK-8检测试剂(#E606335,上海生工)的无酚红培养液替换掉原来的培养液,培养箱中继续培养2h。然后在多功能酶标仪(168-1130,Bio-Rad)上测量OD450nm吸光值(OD值)。受试化合物处理细胞后,细胞生存率(cellsurvival rate)或细胞增殖率(cell growth rate)的计算公式为:生存率=加药组OD值/对照组OD值×100%;化合物对细胞增殖的抑制率(growth inhibition rate)计算公式为:抑制率=(对照组OD值-加药组OD值)/对照组OD值×100%。进一步根据抑制率数值在SPSS中计算出各化合物的IC50。
表2:本发明化合物与苦鬼臼毒素在U87细胞系的IC50数据
实验例2:化合物透过血脑屏障实验-IGF1R信号通路生物标志物检测
试验方法与材料
实验动物来源:SPF级雌性ICR小鼠订购自南京大学-南京生物医药研究院,小鼠周龄为3至5周。
实验动物给药处理:将受试化合物溶解在DMSO(#D5879,Sigma-Aldrich)中,配制成50mg/mL母液。用PBS稀释受试化合物母液,以100mg/kg剂量对小鼠进行灌胃,每种受试化合物设置3只小鼠的实验重复。
检测样品制备:给药3小时后,颈椎脱臼法处死小鼠,取其右脑,加入800μL预冷的细胞裂解液(#P0013,碧云天,新鲜添加入蛋白酶和磷酸酶抑制剂#78444,Thermo FisherScientific),冰浴上充分匀浆,12000rpm离心10分钟后,取上清。用BCA法测定样品的蛋白浓度,加入相应量的4×Laemmli上样缓冲液(#161-0747,Bio-Rad),以3:1体积混合成为脑组织裂解液蛋白样品,100℃金属浴变性8min,12000rpm离心2分钟,取上清进行下列Western blot(免疫印迹试验)检测。
IGF1R信号通路生物标志物检测:将4-15%预制梯度胶(456-8084,Bio-Rad)安装到电泳槽中,加入足量1×SDS-PAGE电泳缓冲液。使用20μL的移液枪加入20μL上述细胞裂解液蛋白样品。将电泳槽盖子盖上,并接通电源,先以80V电压电泳约30min,待样品中溴酚蓝在浓缩胶与分离胶分界线压成一条细线时将电压调至120V,根据目标蛋白以及内参蛋白条带的大小调整电泳持续时间。将预冷1×转膜缓冲液倒入合适大小的容器中,按照说明书组装好泡沫垫-滤纸-胶-PVDF膜-滤纸-泡沫垫的“三明治”结构,装入电泳槽中。加入冰块且整个电泳槽冰浴,连通电源进行转膜,250mA,2h。将PVDF膜(IPVH00010,Millipore)放入由1×TBST配制的5%脱脂奶粉中室温封闭1h。然后依次进行不同一抗(anti-pIGF1R-Y1135/Y1136,#3024S,CST;anti-pAKT-T308,#13038,CST;anti-pAKT-S473,#4060,CST;anti-GAPDH[HRP],#A00191-40,GenScript)和二抗(anti-Mouse IgG HRP-linked antibody,#7076,CST;anti-Rabbit IgG HRP-linked antibody,#7074,CST)的孵育(分别室温孵育1h)与洗膜(1×TBST洗膜3次,每次5min)。最后,将PVDF膜放至塑料膜中间,加入ECL膜上反应3min,盖上另一层塑料膜,在全自动化学发光/荧光图像分析系统(5200-Multi,天能)中曝光。
对照物结构如下所示:
表3:对照物结构
如图1所示,以100mg/kg剂量灌胃给药的化合物1组小鼠,3小时后显著下调了脑组织中的磷酸化IGF1R/AKT等IGF1R信号通路中关键的生物标志物,显著优于其他对照物。
实验例3:化合物透过血脑屏障实验-受试化合物HPLC检测
实验材料与方法
实验动物来源:雄性或雌性BALB/c品系裸鼠订购自上海斯莱克实验动物有限责任公司,小鼠周龄为7周;SPF级雌性ICR小鼠订购自南京大学-南京生物医药研究院,小鼠周龄为5周。
实验动物给药处理:将受试化合物溶解在DMSO(#D5879,Sigma-Aldrich)中,配制成50mg/mL母液。用PBS稀释受试化合物母液,以25mg/kg或50mg/kg剂量对小鼠进行灌胃。
检测样品制备:小鼠分别给药1,3,6,12或24小时后,按250μL/20g体重的剂量腹腔注射4%水合氯醛水溶液,麻醉小鼠,颈动脉取血300μl至肝素管,混匀后,4000rpm 5分钟离心,取上清200μL,加入600μL乙腈,混匀超声20分钟,12000rpm离心10分钟,上清4℃静置过夜,然后12000rpm离心10分钟,取上清作为“血浆检测样品”;取0.3-0.5g左右全脑,用预冷的PBS迅速漂洗3次,加1mL乙腈匀浆(PRIMA手持式匀浆机PB100,35000rpm,1分钟),超声20分钟,12000rpm离心10分钟,上清4℃静置过夜,12000rpm离心10分钟,取上清作为“脑组织检测样品”。
HPLC检测:取上述“血浆检测样品”和“脑组织检测样品”,设置各受试化合物的标准品对照、HPLC流动相空白对照等,用高效液相色谱仪(Hitachi Chromaster-5430检测器,Hitachi Chromaster-5310柱温箱,Hitachi Chromaster-5210自动进样器,HitachiChromaster-5110泵)分析样品中受试化合物的含量。
如图2和图3显示,本发明化合物2、化合物5、化合物6在以50mg/kg灌胃给药1-3小时后在小鼠脑组织和血浆中均可以检测到有效量的化合物,而PPP(苦鬼臼毒素)以50mg/kg灌胃给药1-3小时后在脑组织中检测不到有效量化合物。
如图4和图5显示,本发明化合物6在以50mg/kg灌胃给药后24小时内可以检测到有效量的化合物,化合物7在以25mg/kg灌胃给药后12小时内可以检测到有效量的化合物。
Claims (9)
2.根据权利要求1所述的化合物或其药学上可接受的盐,其特征在于所述化合物选自:
Rel-(5R,5aS,8aR,9R)-2,2-二氟-9-羟基-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6(5aH)-酮;
Rel-(5R,5aR,8aS,9R)-2,2-二氟-8-氧代-9-(3,4,5-三甲氧基苯基)-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-5-基乙酸酯;
Rel-(5R,5aS,8aR,9S)-2,2,9-三氟-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6(5aH)-酮;
Rel-(5R,5aS,8aR,9R)-2,2-二氟-9-甲氧基-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4'6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6-(5aH)-酮;
Rel-(5R,5aS,8aR,9R)-2,2-二氟-9-羟基-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6-(5aH)-酮-9-氘;
(5R,5aS,8aR,9R)-2,2-二氟-9-羟基-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6(5aH)-酮;
(5R,5aS,8aR,9R)-2,2-二氟-9-羟基-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6-(5aH)-酮-9-氘;
(5R,5aR,8aS,9R)-2,2-二氟-8-氧代-9-(3,4,5-三甲氧基苯基)-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-5-基乙酸酯;
(5R,5aS,8aR,9S)-2,2,9-三氟-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6(5aH)-酮;
(5R,5aS,8aR,9R)-2,2-二氟-9-甲氧基-5-(3,4,5-三甲氧基苯基)-5,8,8a,9-四氢呋喃并[3',4'6,7]萘并[2,3-d][1,3]间二氧杂环戊烯-6-(5aH)-酮。
5.一种药物组合物,包括权利要求1-4任一项所述的化合物或其药学上可接受的盐,和药学上可用的载体。
6.权利要求1-4任一项所述的化合物或其药学上可接受的盐在制备胰岛素样生长因子-1受体酪氨酸激酶抑制剂类药物中的用途。
7.权利要求1-4任一项所述的化合物或其药学上可接受的盐在制备预防或治疗抗肿瘤药物中的用途。
8.根据权利要求7所述的用途,其特征在于:所述肿瘤为脑部胶质瘤。
9.根据权利要求8所述的用途,其特征在于:所述脑部胶质瘤为星形细胞瘤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810711045.8A CN110669054B (zh) | 2018-07-03 | 2018-07-03 | 胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810711045.8A CN110669054B (zh) | 2018-07-03 | 2018-07-03 | 胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110669054A CN110669054A (zh) | 2020-01-10 |
CN110669054B true CN110669054B (zh) | 2022-04-26 |
Family
ID=69065962
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810711045.8A Active CN110669054B (zh) | 2018-07-03 | 2018-07-03 | 胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110669054B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021164749A1 (zh) * | 2020-02-20 | 2021-08-26 | 南京药石科技股份有限公司 | 胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途 |
CN112125916A (zh) * | 2020-09-28 | 2020-12-25 | 杭州仁者生物科技有限公司 | 胰岛素样生长因子-1受体的新型小分子抑制剂及其用途 |
CN116143797A (zh) * | 2021-11-19 | 2023-05-23 | 杭州拿因生物科技有限责任公司 | 苦鬼臼毒素衍生物、其药物组合物及用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1543466A (zh) * | 2001-06-19 | 2004-11-03 | 特定环木脂体的新用途 | |
EP1073654B1 (en) * | 1998-04-21 | 2008-07-16 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
CN103269700A (zh) * | 2010-10-08 | 2013-08-28 | 阿克塞拉公司 | 用于癌症治疗的鬼臼苦素多晶型b或c |
-
2018
- 2018-07-03 CN CN201810711045.8A patent/CN110669054B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1073654B1 (en) * | 1998-04-21 | 2008-07-16 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
CN1543466A (zh) * | 2001-06-19 | 2004-11-03 | 特定环木脂体的新用途 | |
CN103269700A (zh) * | 2010-10-08 | 2013-08-28 | 阿克塞拉公司 | 用于癌症治疗的鬼臼苦素多晶型b或c |
Also Published As
Publication number | Publication date |
---|---|
CN110669054A (zh) | 2020-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102368298B1 (ko) | 질소-함유 트라이사이클릭 화합물, 및 의약에서 이의 용도 | |
CN110669054B (zh) | 胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途 | |
CN104039796B (zh) | 1-氧代/酰化-14-酰化的冬凌草甲素衍生物、及其制备方法和应用 | |
EP3268004A1 (en) | Pyrrolopyridazine inhibitors of irak4 activity | |
UA126349C2 (uk) | Заміщені біциклічні гетероциклічні сполуки як інгібітори prmt5 | |
CN114315848B (zh) | 胰岛素样生长因子-1受体的小分子抑制剂及其用途 | |
Lee et al. | Three new megastigmane glucopyranosides from the Cardamine komarovii | |
Deng et al. | Cantharidin derivatives from the medicinal insect Mylabris phalerata | |
WO2012010555A1 (en) | Tricyclic lactones for treatment of cancer | |
Gu et al. | Gelserancines A–E, monoterpenoid indole alkaloids with unusual skeletons from Gelsemium elegans | |
CN107056680B (zh) | 含二氟甲基的螺[环丙烷-1,3′-吲哚啉]-2′-酮类化合物和药物用途 | |
Wei et al. | Novel phthalide dimers from the aerial parts of Ligusticum sinense Oliv cv. Chaxiong | |
CN111620920B (zh) | 一种用于治疗肿瘤的黄酮衍生物及其应用 | |
CN116113698A (zh) | Trpml调节剂 | |
CN109897022B (zh) | 含笑内酯衍生物、其药物组合物及其制备方法和用途 | |
JP2011506351A (ja) | α−アミノ基−N−置換アミド化合物、該化合物を含む薬剤組成物及びその用途 | |
JP7096559B2 (ja) | トリプトリド誘導体およびその製造方法と使用 | |
Lo et al. | Sinuladiterpenes A–F, new cembrane diterpenes from Sinularia flexibilis | |
WO2021164749A1 (zh) | 胰岛素样生长因子-1受体酪氨酸激酶抑制剂及其用途 | |
RU2686675C1 (ru) | Таксановые соединения, а также способ их получения и их применения | |
CN104003998B (zh) | 冬凌草甲素14-o-取代氮芥衍生物、制备方法及用途 | |
KR20120084772A (ko) | 할로겐화 다이디옥시글루코오스 유도체 및 그 제조방법과 그 용도 | |
Alonso-Fernandez et al. | Synthetic studies on Stemona alkaloids. Construction of the sessilifoliamides B and C and 1, 12-secostenine skeleton | |
CN109232710B (zh) | 一类特殊的异甾体生物碱及其衍生物的制备方法 | |
TW202114710A (zh) | 作為sting促效劑之環狀二核苷酸 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20231128 Address after: Room 398, Building A, Phase I, Zhongdan Ecological Life Science Industrial Park, No. 3-1 Xinjinhu Road, Jiangbei New District, Nanjing City, Jiangsu Province, 210032 Patentee after: Nanjing Maisheng Technology Co.,Ltd. Address before: No. 10, Xuefu Road, Nanjing high tech Industrial Development Zone, Nanjing, Jiangsu 210032 Patentee before: PHARMABLOCK SCIENCES (NANJING) , Inc. |